Reduced representative methylome profiling of cell-free DNA for breast cancer detection

Clin Epigenetics. 2024 Feb 27;16(1):33. doi: 10.1186/s13148-024-01641-x.

Abstract

Background: Whole-genome methylation sequencing of cfDNA is not cost-effective for tumor detection. Here, we introduce reduced representative methylome profiling (RRMP), which employs restriction enzyme for depletion of AT-rich sequence to achieve enrichment and deep sequencing of CG-rich sequences.

Methods: We first verified the ability of RRMP to enrich CG-rich sequences using tumor cell genomic DNA and analyzed differential methylation regions between tumor cells and normal whole blood cells. We then analyzed cfDNA from 29 breast cancer patients and 27 non-breast cancer individuals to detect breast cancer by building machine learning models.

Results: RRMP captured 81.9% CpG islands and 75.2% gene promoters when sequenced to 10 billion base pairs, with an enrichment efficiency being comparable to RRBS. RRMP allowed us to assess DNA methylation changes between tumor cells and whole blood cells. Applying our approach to cfDNA from 29 breast cancer patients and 27 non-breast cancer individuals, we developed machine learning models that could discriminate between breast cancer and non-breast cancer controls (AUC = 0.85), suggesting possibilities for truly non-invasive cancer detection.

Conclusions: We developed a new method to achieve reduced representative methylome profiling of cell-free DNA for tumor detection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / genetics
  • Cell-Free Nucleic Acids* / genetics
  • CpG Islands
  • DNA Methylation
  • Epigenome
  • Female
  • Humans

Substances

  • Cell-Free Nucleic Acids